Loading
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Latest quote
$35.21
−$0.27 · -0.76%
Regular session · ET · Market data may be delayed.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
31
Expensive
Sentiment
63
Bullish
Risk
57
Elevated Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 19, 2023 | 1:4 | — | — |
Stock split | Sep 25, 2023 | 1:5 | — | — |
Effective Dec 19, 2023
1:4
Effective Sep 25, 2023
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM10.56M0.01%78.38B USD0.19%$287.91-0.34%
iShares Biotechnology ETFIBB4.27M0.04%10.34B USD0.44%$204.6+0.82%
Fidelity Enhanced Small Cap ETFFESM3.8M0.06%6.49B USD0.28%$46.15-0.45%
Vanguard Russell 2000 ETFVTWO2.09M0.01%17.4B USD0.06%$116.37-0.33%
iShares Micro-Cap ETFIWC1.37M0.09%1.44B USD0.60%$190.92+0.04%
Vanguard Health Care ETFVHT1.03M0.00%20.9B USD0.09%$315.02+1.38%
Avantis U.S. Small Cap Equity ETFAVSC997.16K0.03%3.09B USD0.25%$71.285-0.27%
ALPS Medical Breakthroughs ETFSBIO773.25K0.33%232.86M USD0.50%$63.71+0.66%iShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAvantis U.S. Small Cap Equity ETFAVSCALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
